Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice

Asthma phenotyping and endotyping are constantly evolving. Currently, several biologic agents have been developed towards a personalized approach to asthma management. This review will focus on different eosinophilic phenotypes and Th2-associated endotypes with eosinophilic inflammation. Additionally, airway remodeling is analyzed as a key feature of asthmatic eosinophilic endotypes. In addition, evidence of biomarkers is examined with a predictive value to identify patients with severe, uncontrolled asthma who may benefit from new treatment options. Finally, there will be a discussion on the results from clinical trials regarding severe eosinophilic asthma and how the inhibition of the eosinophilic pathway by targeted treatments has led to the reduction of recurrent exacerbations.

Automated summary

This review focuses on different eosinophilic phenotypes and Th2-associated endotypes in asthma, as well as the importance of airway remodeling in eosinophilic endotypes. It examines the evidence of biomarkers for identifying patients with severe, uncontrolled asthma who may benefit from new treatment options. Furthermore, it discusses the results of clinical trials regarding severe eosinophilic asthma and the reduction of recurrent exacerbations through targeted treatment.